Skip to main content
SpringerLink
Log in

Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

    Article  CAS  PubMed  Google Scholar 

  2. Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, et al. Early experience of rechallenge (177)Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC. J Nucl Med. 2019;60:644–8.

    Article  CAS  PubMed  Google Scholar 

  3. Gafita A, Bieth M, Kroenke M, et al. qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET/CT. J Nucl Med 2019.

  4. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Isaacsson Velho P, Qazi F, Hassan S, et al. Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.09.040.

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany

    Andrei Gafita, Hui Wang, Calogero D’Alessandria, Wolfgang A. Weber & Matthias Eiber

  2. School of Medicine, Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany

    Robert Tauber

Authors
  1. Andrei Gafita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Tauber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Calogero D’Alessandria
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang A. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matthias Eiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrei Gafita.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the Month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gafita, A., Wang, H., Tauber, R. et al. Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 46, 2212–2213 (2019). https://doi.org/10.1007/s00259-019-04410-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04410-8

Search

Navigation